Eight patients had a complete response within 1 month of infusion.
The model appears to predict minimal residual disease status.
Confirmed undetectable MRD after 12 cycles may result in treatment discontinuation.
The bispecific CAR-T therapy targets CD20 and CD19.
Even patients who did not achieve MRD negativity at 1 year had stable or decreasing disease levels.
Asciminib may be a new treatment option for patients with chronic myeloid leukemia in the chronic phase (CML-CP).
Dr Samur and colleagues found that high-dose melphalan caused an approximately 2.5-fold greater mutation accumulation rate than that observed with RVD treatment alone.
Now that the phase 2 dose is established, a randomization cohort will test the efficacy of the treatments in the LACEWING trial.
Census tract affluence, disadvantage, and segregation were all significant predictors of leukemia-related death.
